MAIA Biotechnology, Inc. ((MAIA)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MAIA Biotechnology, Inc. is conducting a Phase 2 clinical study titled ‘A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)’. The study aims to evaluate the efficacy of THIO, a telomere targeting agent, in combination with cemiplimab, a PD-1 inhibitor, to restore tumor responses in patients with advanced NSCLC who have developed resistance or relapsed after initial treatment.
The intervention involves the use of 6-Thio-2′-Deoxyguanosine (THIO) and cemiplimab. THIO targets telomeres in cancer cells, leading to cell death, while cemiplimab is used to inhibit PD-1, enhancing immune response against cancer cells.
This interventional study is randomized and follows a sequential intervention model with no masking. The primary purpose is treatment-focused, aiming to find the optimal dose and assess the combination’s safety and efficacy.
The study began on December 5, 2021, with the last update submitted on May 27, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature, providing a timeline for potential results and future updates.
For investors, this study could influence MAIA Biotechnology’s stock performance positively if successful, given the potential breakthrough in NSCLC treatment. The competitive landscape includes other companies developing similar immunotherapy combinations, which could impact market dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.